Send to

Choose Destination
Sci Rep. 2017 Feb 23;7:43379. doi: 10.1038/srep43379.

Evidence for Critical Role of Lymphocyte Cytosolic Protein 1 in Oral Cancer.

Author information

Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba, Japan.
Department of Dentistry and Oral-Maxillofacial Surgery, Chiba University Hospital, Chiba, Japan.
Department of Oral Surgery, Kashima Rosai Hospital, Ibaraki, Japan.
Department of Oral and maxillofacial Surgery Research Institute, National Defense Medical College, Saitama, Japan.
Department of Dentistry and Oral-Maxillofacial Surgery, Japanese Red Cross Fukaya Hospital, Saitama, Japan.
Department of Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.


Lymphocyte cytosolic protein 1 (LCP1), a member of actin-binding protein of the plastin family, has been identified in several malignant tumors of non-hematopoietic sites, such as the colon, prostate, and breast. However, little is known about the roles of LCP1 in oral squamous cell carcinomas (OSCCs). This present study sought to clarify the clinical relevance of LCP1 in OSCCs and investigate possible clinical applications for treating OSCCs by regulating LCP1 expression. We found up-regulation of LCP1in OSCCs compared with normal counterparts using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), immunoblotting, and immunohistochemistry (P < 0.05). We used shRNA models for LCP1 (shLCP1) and enoxacin (ENX), a fluoroquinolone antibiotic drug, as a regulator of LCP1 expression. In addition to the LCP1 knockdown experiments in which shLCP1 cells showed several depressed functions, including cellular proliferation, invasiveness, and migratory activities, ENX-treated cells also had attenuated functions. Consistent with our hypothesis from our in vitro data, LCP1-positive OSCC samples were correlated closely with the primary tumoral size and regional lymph node metastasis. These results suggested that LCP1 is a useful biomarker for determining progression of OSCCs and that ENX might be a new therapeutic agent for treating OSCCs by controlling LCP1 expression.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center